BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30290085)

  • 1. Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology.
    Bastida JM; López-Godino O; Vicente-Sánchez A; Bonanad-Boix S; Xicoy-Cirici B; Hernández-Sánchez JM; Such E; Cervera J; Caballero-Berrocal JC; López-Cadenas F; Arnao-Herráiz M; Rodríguez I; Llopis-Calatayud I; Jiménez MJ; Del Cañizo-Roldán MC; Díez-Campelo M
    Int J Lab Hematol; 2019 Feb; 41(1):109-117. PubMed ID: 30290085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinically relevant possibilities and limits of differential diagnosis of megaloblastic anemia and myelodysplastic syndrome - refractory anemia type in bone marrow biopsies].
    Vašeková P; Szépe P; Marcinek J; Balhárek T; Plank L
    Vnitr Lek; 2016; 62(9):692-697. PubMed ID: 27715070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
    Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
    Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
    Malcovati L; Cazzola M
    Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
    Xiong B; Xue M; Yu Y; Wu S; Zuo X
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
    Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
    Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
    Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
    Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
    Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
    Malcovati L; Stevenson K; Papaemmanuil E; Neuberg D; Bejar R; Boultwood J; Bowen DT; Campbell PJ; Ebert BL; Fenaux P; Haferlach T; Heuser M; Jansen JH; Komrokji RS; Maciejewski JP; Walter MJ; Fontenay M; Garcia-Manero G; Graubert TA; Karsan A; Meggendorfer M; Pellagatti A; Sallman DA; Savona MR; Sekeres MA; Steensma DP; Tauro S; Thol F; Vyas P; Van de Loosdrecht AA; Haase D; Tüchler H; Greenberg PL; Ogawa S; Hellstrom-Lindberg E; Cazzola M
    Blood; 2020 Jul; 136(2):157-170. PubMed ID: 32347921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or
    Mortuza S; Chin-Yee B; James TE; Chin-Yee IH; Hedley BD; Ho JM; Saini L; Lazo-Langner A; Schenkel L; Bhai P; Sadikovic B; Keow J; Sangle N; Hsia CC
    Curr Oncol; 2024 Mar; 31(4):1762-1773. PubMed ID: 38668037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic Syndrome Updated.
    Hasserjian RP
    Pathobiology; 2019; 86(1):7-13. PubMed ID: 30041243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
    Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
    Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.
    Rauw J; Wells RA; Chesney A; Reis M; Zhang L; Buckstein R
    Leuk Res; 2011 Oct; 35(10):1335-8. PubMed ID: 21704372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reclassifying myelodysplastic syndromes: what's where in the new WHO and why.
    Arber DA; Hasserjian RP
    Hematology Am Soc Hematol Educ Program; 2015; 2015():294-8. PubMed ID: 26637736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case 37: Neutropenia and macrocytosis in a middle-aged man.
    Mangles SE; Abdalla SH; Gabriel CM; Bain BJ
    Leuk Lymphoma; 2007 Sep; 48(9):1846-8. PubMed ID: 17786722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
    Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
    Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexplained macrocytosis.
    Younes M; Dagher GA; Dulanto JV; Njeim M; Kuriakose P
    South Med J; 2013 Feb; 106(2):121-5. PubMed ID: 23380746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.